Clinical Trial Update: Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial examining cisplatin with or without the WEE1 inhibitor MK-1775 in recurrent or metastatic head and neck cancers was terminated; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypopharyngeal Cancer
• Laryngeal Cancer
• Lip Cancer
• Nasal Cavity Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Paranasal Sinus Cancer
• Tongue Cancer

Drugs mentioned

• MK-1775 (adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-03